No Data
No Data
No Data
No Data
No Data
麗珠醫藥:2023年報
Futu NewsApr 29 17:42 · Announcements
Pearl Group (000513): Steady performance, optimistic about long-term innovation and implementation
Maintain an “Overweight” rating. 2024Q1 revenue of 3.243 billion yuan (-5.0%), net profit attributable to mother of 608 million yuan (+4.5%), net profit after deducting non-attributable net profit of 590 million yuan (+3.6%), gross profit margin
國泰君安Apr 28 18:06
Express News | Nanjing Jianyou and Livingzhu Group collaborated to export injectable cetrorelix acetate to the US for the first time
BreakingsApr 28 11:45
Dongwu Securities released a research report on April 26 stating that it gave the Pearl Group (000513.SZ) a buying rating. The main reasons for the rating include: 1) the gonadotropin and diagnostic reagent sector grasped the impressive growth rate of mar
Dongwu Securities released a research report on April 26 stating that it gave the Pearl Group (000513.SZ) a buying rating. The main reasons for the rating include: 1) the gonadotropin and diagnostic reagent sector grasped the impressive growth rate of market demand, and overall revenue and profit were in line with expectations; 2) they were optimistic about the accelerated implementation of high-end formulations and biopharmaceutical pipelines, and incremental products contributed to a peak sales of 6.5 billion yuan. (Mainichi Keizai Shimbun)
Zhitong FinanceApr 26 19:45
Pearl Group (000513): Excellent performance in the field of promotion and diagnostic reagents, and steady overall profit
Key investment events: The company announced its results for the first quarter of 2024. In 24Q1, the company achieved revenue of 3.243 billion yuan (-4.99%, same as below) and net profit to mother of 608 million yuan (+4.45%).
東吳證券Apr 26 19:21
Express News | Livou Group: The company obtained approval from the US FDA for injectable cetrorelix acetate
BreakingsApr 26 18:21
No Data
No Data